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undertreated patients; there were no differences in SF-8 Physical
Component Summary scores by group. CONCLUSIONS:
Depressive symptoms are common in patients diagnosed with
ACS and appear to be related to lower mental HRQL. Though
the need for prospective analyses remains, these observations
stress the importance of identiﬁcation of depressive symptoms in
this population and initiation of appropriate psychotherapeutic
treatment.
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OBJECTIVES: To assess health status in high-risk subjects
undergoing noncardiac vascular surgery in the United States.
METHODS: Health status data were collected as part of a phar-
macoeconomic (PE) substudy from a clinical trial in noncardiac
vascular surgery patients. The analysis population consisted of
subjects (mean age = 70.0) from the primary clinical analysis
population of U.S. subjects who consented to participate in the
PE substudy. Health status was measured using the 12-item
Short-Form Health Survey (SF-12 acute, version 1) at baseline
and post-operative Day 30. Physical and mental component
summary scores (PCS and MCS) were calculated using published
scoring algorithms. RESULTS: Of the 370 subjects in the U.S.
clinical population, 229 subjects (62%) provided information on
the SF-12. Differences in the distribution of age, gender, race,
and index procedures were similar in both clinical and PE sub-
study samples. Mean scores were 30.6 (SD = 10.7) at baseline
and 32.8 (10.6) at Day 30 for the PCS; corresponding scores
were 50.3 (12.4) and 50.4 (10.5) for the MCS. There was a slight
improvement in the mean change from baseline for the PCS and
no real improvement for the MCS. The proportion of patients
whose SF-12 scores improved from baseline was 54.2% and
45.9% for the PCS and MCS, respectively. Mean baseline SF-12
scores on the PCS for these subjects were noticeably lower than
those from the general U.S. population norms aged 65–74 (PCS
mean = 43.9, SD = 9.3) and from other common chronic dis-
eases. CONCLUSIONS: The data suggest a marginal improve-
ment in PCS, but not MCS scores at post-operative Day 30. A
longer follow-up may have been necessary to detect a noticeable
improvement in health status. High-risk patients undergoing
noncardiac vascular surgery have relatively low levels of 
physical functioning and well-being compared with many other
diseases.
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OBJECTIVE: Assessment of quality of drug treatment can be
expensive and time consuming. Database of sickness fund was
used and a set of non-speciﬁc and disease-speciﬁc indicators
according to treatment guidelines was developed to assess the
quality of drug treatment of coronary artery disease (CAD) in
counties population. METHODS: Patients from 5 selected coun-
ties in Slovak Republic treated for CAD were identiﬁed from
database of General Sickness Fund. Overall prescribed treatment
for CAD in 2001 was assessed according to the quantity and
quality of prescribed drugs using developed set of 10 quality indi-
cators. RESULTS: A total of 52,487 patients (10.3%) were
treated for CAD, 65% were female. The mean age was 68.3
years. Seventy-seven percent were also receiving treatment for
hypertension and 18% had diabetes. Sixty-ﬁve percent were
treated with long-acting nitrates, and in almost 25%, long-acting
nitrates were the only treatment for CAD. Sixty percent were not
receiving beta-blocking agents. Antithrombotic therapy was 
prescribed for two thirds of patients. Only 15% were receiving
hypolipidemic agents. Performance in each county using 10
quality indicators was assessed separately and huge differences
between counties were found. CONCLUSIONS: The overall
score achieved with quality indicators was unsatisfactory. The
results show low compliance of physicians with existing guide-
lines and the need for activities for improving the quality of drug
treatment of CAD.
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OBJECTIVES: The purpose of this study is to compare medica-
tion adherence in patients initiated on a combination therapy of
Calcium Channel Blockers (CCB) and Statins with those on CCB
or Statins mono-therapy. METHODS: Using pharmacy claims
data of a California Medicaid population from 1995 to 2002,
we computed a 90, 180, 270 and 365-day Medication Posses-
sion Ratio (MPR) for the purpose of measuring medication
adherence. Four patient cohorts are compared: 1) CCB only (N
= 33,367); 2) Statins only (N = 27,536); 3) Combination
Therapy: CCB + Statin (initiated on CCB, Statin addition) (N =
14,866); and 4) Combination Therapy: Statin + CCB (initiated
on Statin, CCB addition) (N = 5944). Patients with both a CCB
and a Statin medication ﬁlled on the same day (N = 1265) are
included in both Cohorts 3 and 4. Patients must have Medicaid
coverage for at least six months prior to initial CCB or Statin
medication use to be included in the analysis. Continued eligi-
bility for an adequate length of time is required to compute MPR
for given days (e.g., 3 months continued eligibility to compute a
90-day MPR). RESULTS: The average 180-day MPR was 54.5%
for Cohort 3 and 52.1% for Cohort 4, which is lower than that
of CCB and Statin mono-therapy (56.5% and 59.7%, respec-
tively). However, the average MPR for the combination therapy
increased to 64.4% with the addition of a CCB and to 65.2%
with the addition of a Statin. In general, average MPRs increased
over the years. For the Statins-only cohort, the 180-day MPR
increased from 50.8% in 1995 to 64.2% in 2001. CONCLU-
SIONS: Multiple medications appear to reduce medication
adherence. For patients using combination therapy of CCBs and
Statins, it may be beneﬁcial to develop a combination drug to
improve medication adherence.
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OBJECTIVES: The goal of this study is to evaluate patient per-
sistence and adherence rates to HMG-CoA reductase inhibitors
(statins) in a managed care setting. METHODS: Retrospective
claims analysis of a nationwide managed care pharmacy data-
base was conducted for continuously beneﬁt-eligible patients
who were initiated on statin therapy from 1999 to 2002. Patients
were tracked for 12 months starting from the date of initial
